Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Murtaza K. Adam, MD, of Colorado Retina Associates, discusses real-world data coming in 2026.
He said he is excited about data on Eylea HD (aflibercept 8 mg, Regeneron).
Adam said there is already “robust” real-world data on Vabysmo (faricimab-svoa, Genentech) in neovascular age-related macular degeneration and diabetic macular edema, and “we are looking forward to seeing how the second-generation molecules altogether fare and compare to one another.”